Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
16.98
+0.03 (0.18%)
Jun 15, 2026, 10:18 AM EDT - Market open
Nurix Therapeutics Revenue
Nurix Therapeutics had revenue of $6.25M in the quarter ending February 28, 2026, a decrease of -66.12%. This brings the company's revenue in the last twelve months to $71.78M, up 27.23% year-over-year. In the fiscal year ending November 30, 2025, Nurix Therapeutics had annual revenue of $83.98M with 53.95% growth.
Revenue (ttm)
$71.78M
Revenue Growth
+27.23%
P/S Ratio
24.42
Revenue / Employee
$226,432
Employees
317
Market Cap
1.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Nov 30, 2025 | 83.98M | 29.43M | 53.95% |
| Nov 30, 2024 | 54.55M | -22.44M | -29.15% |
| Nov 30, 2023 | 76.99M | 38.36M | 99.31% |
| Nov 30, 2022 | 38.63M | 8.88M | 29.84% |
| Nov 30, 2021 | 29.75M | 11.93M | 66.95% |
| Nov 30, 2020 | 17.82M | -13.30M | -42.73% |
| Nov 30, 2019 | 31.12M | -6.33M | -16.91% |
| Nov 30, 2018 | 37.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Innoviva | 420.69M |
| Iovance Biotherapeutics | 285.61M |
| Nuvation Bio | 143.05M |
| Viridian Therapeutics | 70.92M |
| Intellia Therapeutics | 66.09M |
| Agios Pharmaceuticals | 66.05M |
| Mesoblast | 65.38M |
| Nanobiotix | 38.27M |
NRIX News
- 4 days ago - Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy - GlobeNewsWire
- 6 days ago - Nurix Therapeutics price target raised to $32 from $30 at Truist - TheFly
- 6 days ago - Nurix Therapeutics price target raised to $32 from $30 at BTIG - TheFly
- 6 days ago - Nurix Therapeutics price target raised to $32 from $30 at Truist - TheFly
- 6 days ago - Nurix Therapeutics price target raised to $45 from $41 at Jefferies - TheFly
- 6 days ago - Nurix Therapeutics price target raised to $34 from $26 at Needham - TheFly
- 7 days ago - This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug - Barrons
- 7 days ago - Nurix Therapeutics downgraded to Equal Weight at Wells Fargo after Roche deal - TheFly